In vivo biomarkers of GABAergic function in epileptic rats treated with the GAT-1 inhibitor E2730.

Idrish AliBianca JuppMatthew R HudsonBrendan MajorJuliana C SilvaGlenn R YamakawaPablo Miguel Casillas-EspinosaEmma BrainePeravina ThergarajanMohammad B HaskaliLucy E VivashRobert BrkljacaSandy R ShultzPatrick KwanKazuyuki FukushimaPallavi SachdevJocelyn Y ChengRichelle MychasiukNigel Charles JonesDavid K WrightTerence J OBrien

Published in: Epilepsia (2024)

This study identified clinically relevant changes in multimodality imaging and functional purported biomarkers of GABAergic activity during E2730 treatment in epileptic and healthy control animals. These biomarkers could be utilized in clinical trials of E2730 and potentially other GABAergic drugs to provide surrogate endpoints, thereby reducing the cost of such trials.

Keyphrases

clinical trial
high resolution
randomized controlled trial
combination therapy
photodynamic therapy
replacement therapy